Linked Life Data

788739

Source:http://linkedlifedata.com/resource/pubmed/id/788739

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1977-1-3
pubmed:abstractText
1 Phenylbutazone in doses of 50, 100, 200 and 300 mg/day has been given for four periods of 3 weeks to seven patients with rheumatoid arthritis. The trial was double-blind and the order of administration of doses was arranged to eliminate order and carry-over effects. 2 Before the trial and at the end of each period, the patient's responses were assessed by measurement of the duration of morning stiffness, the pain score, paracetamol tablet count, grip strength, digital joint size and articular index. 3 The plasma phenybutazone concentration was measured by gas-liquid chromatography and was also predicted by prior measurement of the phenazone half-life. 4. Compared with the pretreatment period, phenylbutazone had a significant therapeutic effect, as judged by morning stiffness, pain score and articular index, in a dose of 50 mg/day, but no statistically significant differences in effect were seen between the various doses of phenylbutazone. 5 There were no significant coorelations between the plasma concentration of phenylbutazone and any of the clinical assessments. 6 The plasma phenylbutazone concentration agreed closely with that predicted at doses of 50 and 100 mg, but at higher doses the plasma concentration was significantly lower than predicted (P less than 0.05). This may have been due to saturation of the protein binding sites at these doses.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-13109696, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-13124349, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-13131825, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-4453937, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-4592672, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-4594449, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-4603132, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-4769061, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-4861386, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-4877784, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-5316400, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-5753556, http://linkedlifedata.com/resource/pubmed/commentcorrection/788739-5884654
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
185-91
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1976
pubmed:articleTitle
Plasma concentration of phenylbutazone and its therapeutic effect-studies in patients with rheumatoid arthritis.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Controlled Clinical Trial